AstraZeneca Investor Science Event at ASCO 2016

AstraZeneca provided a presentation for investors and analysts during the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The event took place on Monday 6 June 2016 from 19:00 - 20:30 CDT (7 June 01:00 - 02:30 BST). We provided an update on progress in Oncology, including launch medicines and the immuno-oncology and small-molecule pipeline. For those who were unable to attend, please find further details including replay information by clicking the link 'read more'. The presentation is also available via the direct download link below.

Financial calendar


Upcoming events

Investor roadshows in London, Edinburgh, Europe and North America

Attendance: Management

Ex-dividend date (New York ADS)


Past events


Past events



JP Morgan Healthcare Conference

Pascal Soriot, Chief Executive Officer, AstraZeneca presented an update on the company’s development pipeline and outline its strategic priorities for 2014 as AstraZeneca continues to focus on achieving scientific leadership and returning to growth.


Fostamatinib analyst briefing

Download presentation.

Third quarter and nine months results 2012

Download presentation and analyst call script.


Investor information

This may not be the latest available data

Financial results

Total revenue
↑ 1% at CER

Core earnings per share
↑ 7% at CER


Latest results and presentations

General investor presentation

Materials available: 1

AstraZeneca Investor Science Event at ASCO 2016

Materials available: 1

Annual Report websites

Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.


Investor notes

I/O combo data updated at SITC - durvalumab plus tremelimumab combination data in lung cancer (6 November 2015)

AstraZeneca Investor Relations Team's Briefing Note regarding updated combination data presented at the Society for Immunotherapy in Cancer (SITC) on Friday 6 November 2015.

AstraZeneca refines its financial reporting in line with evolving business model (6 March 2015)

AstraZeneca announced an update to the presentation of its Statement of Comprehensive Income, which will see revenue from externalisation becoming more visible to enhance transparency for investors.

Accounting for the US Branded Pharmaceutical Fee (7 January 2015)

In mid 2014 the Internal Revenue Service issued final regulations that affected how the annual branded pharmaceutical fee, imposed by the health care reform legislation in 2010 is recognised. As a result, entities covered by the legislation will now accrue for the obligation as each sale occurs. AstraZeneca recorded a catch-up charge to SG&A, reflecting this new basis, as part of its Q3 2014 results.

Diabetes alliance transaction overview (19 December 2014)

Contact us

UK investor enquiries

Main Contacts

UK general enquiries

Thomas Kudsk Larsen

Nick Stone

Respiratory, Inflammation and Autoimmunity

Henry Wheeler


Craig Marks


Christer Gruvris

Infection, Neuroscience and Gastrointestinal

US investor enquiries

Mai contacts

US general enquires

Lindsey Trickett

Cardiovascular and Metabolic diseases

Mitch Chan


  • Annual Reports

    Our Annual Report provides a wide range of information about our global business.

  • Shareholder FAQs

    Answers to frequently asked shareholder questions.

  • Our Pipeline

    Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development